Pancreatic neuroendocrine tumors: Role of novel agents

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 117-119

  Strimpakos, Alexios S ^a   Syrigos, Konstantinos N ^a   Saif, Muhammad Wasif ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

Everolimus; Molecular targeted therapy; Neuroendocrine tumors; Pancreatic neoplasms; Sunitinib; Tor serine threonine kinases

Indexed keywords

ANTHRACYCLINE; ETOPOSIDE; EVEROLIMUS; FLUOROPYRIMIDINE; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB;

ADVANCED CANCER; ANEMIA; ARTICLE; CHEST INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPERGLYCEMIA; JAPANESE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; TUBEROUS SCLEROSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; SIROLIMUS; TREATMENT OUTCOME;

EID: 79952797466     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009; 14:456-467. [PMID 19411317]
2. Yao J, Shah M, Ito T, Lombard-Bohas C, Wolin E, Van Cutsem E, et al. A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann Oncol 2010; 21(Suppl 8):84-85.
3. Valle J, Faivre S, Raoul J, Bang Y, Patyna S, Lu D, et al. Phase III trial of sunitinib (SU) versus placebo (PLO) for treatment of pancreatic neuroendocrine tumors (NET): impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS). Ann Oncol 2010; 21(Suppl 8):8264.
4. Castellano D, Capdevilla J, Salazar R, Sastre J, Alonso V, M. Llanos, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of Spanish neuroendocrine tumor group (GETNE-0801). Ann Oncol 2010; 21(Suppl 8):8265.
5. Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). J Clin Oncol 2011; 29(Suppl. 4):Abstract 278.
6. Ito T, Okusaka T, Ikeda M, Tajima T, Kasuga A, Fujita Y, Furuse Y. Everolimus versus placebo in Japanese patients with advanced pancreatic neuroendocrine tumors (pNET): Japanese subgroup analysis of RADIANT-3. J Clin Oncol 2011; 29(Suppl. 4):Abstract 289.
7. Strosberg JR, Cheema A, Campos T, Valone T, Kvols LK. Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors. J Clin Oncol 2011; 29(Suppl. 4):Abstract 244.
8. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009; 35: 148-159. [PMID 19013721]